Rami Komrokji, MD | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Rami Komrokji, MD

  1. Home
Position / Title: 
Clinical Director, Malignant Hematology Department Lead Clinical Investigator, MDS Program
Institution: 
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Online Profile: 
https://moffitt.org/research-science/researchers/rami-komrokji/
Primary Disease Area of Focus: 
  • Acute Myeloid Leukemia (AML)
  • Aplastic Anemia
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
Practice Location: 
H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Tampa , FL ,
US
Physician Status: 
  • accepting new patients

Other pages on our site that mention Rami Komrokji:

  1. Article - How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji
  2. Page - Medical Advisory Board
  3. Research Article - Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
  4. Research Article - Luspatercept in the treatment of lower-risk myelodysplastic syndromes
  5. Research Article - Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
  6. Research Article - TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  7. Research Article - Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
  8. Research Article - SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
  9. Research Article - Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure